According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is A$56.25 Million. In 2022 the company made a revenue of -A$49.7 Million a decrease over the revenue in the year 2021 that were of A$21.37 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.